Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 5721 | 2019 |
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ... New England journal of medicine 380 (24), 2295-2306, 2019 | 4982 | 2019 |
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1332 | 2018 |
Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ... Jama 321 (1), 69-79, 2019 | 1076 | 2019 |
Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial N Sherry, W Hagopian, J Ludvigsson, SM Jain, J Wahlen, RJ Ferry, ... The Lancet 378 (9790), 487-497, 2011 | 542 | 2011 |
Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized … S Del Prato, AH Barnett, H Huisman, D Neubacher, HJ Woerle, KA Dugi Diabetes, Obesity and Metabolism 13 (3), 258-267, 2011 | 442 | 2011 |
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized … M Jadzinsky, A Pfützner, E Paz‐Pacheco, Z Xu, E Allen, R Chen, ... Diabetes, Obesity and Metabolism 11 (6), 611-622, 2009 | 395 | 2009 |
Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups: results … KW Mahaffey, MJ Jardine, S Bompoint, CP Cannon, B Neal, ... Circulation 140 (9), 739-750, 2019 | 264 | 2019 |
Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind … RE Ratner, J Rosenstock, G Boka, DRI6012 Study Investigators Diabetic Medicine 27 (9), 1024-1032, 2010 | 198 | 2010 |
Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial LM Ruilope, R Agarwal, SD Anker, GL Bakris, G Filippatos, C Nowack, ... American journal of nephrology 50 (5), 345-356, 2019 | 173 | 2019 |
Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA DK McGuire, JH Alexander, OE Johansen, V Perkovic, J Rosenstock, ... Circulation 139 (3), 351-361, 2019 | 164 | 2019 |
Цукровий діабет і ожиріння–епідемія ХХІ століття: сучасний підхід до проблеми МВ Власенко, ІВ Семенюк, ГГ Слободянюк Український терапевтичний журнал 2, 50-5, 2011 | 91 | 2011 |
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled … M von Herrath, SC Bain, B Bode, JO Clausen, K Coppieters, L Gaysina, ... The Lancet Diabetes & Endocrinology 9 (4), 212-224, 2021 | 89 | 2021 |
Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease Z Zhou, MJ Jardine, Q Li, BL Neuen, CP Cannon, D De Zeeuw, ... Stroke, 2021 | 74 | 2021 |
Ендокринологія ПН Боднар, ЮІ Комісаренко, ГП Михальчишин, МІ Бобрик, ... Нова Книга, 2020 | 65 | 2020 |
Эндокринология ПН Боднар, ГП Михальчишин, ЮИ Комиссаренко, АМ Приступюк, ... Нова Книга, 2016 | 56 | 2016 |
Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes AP Sykes, GL Kemp, R Dobbins, R O'Connor‐Semmes, SR Almond, ... Diabetes, Obesity and Metabolism 17 (1), 98-101, 2015 | 37 | 2015 |
Сучасні класифікації та стандарти лікування розповсюджених захворювань внутрішніх органів ЮМ Мостовий Вінниця.-(14-е вид., доп. і перероб.).-С 218, 226, 2011 | 24 | 2011 |
Терапевтические маски гипотиреоза ВС Вернигородский, МВ Власенко, АВ Паламарчук, ... Международный эндокринологический журнал 14 (5), 503-507, 2018 | 17 | 2018 |
Сучасні класифікації та стандарти лікування захворювань внутрішніх органів. Невідкладні стани в терапії. Аналізи: нормативні показники, трактування змін, 2018 ЮМ Мостовой, ГВ Демчук, ТВ Константинович, ЛВ Распутіна, ... | 14 | 2018 |